Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.49 |
| ▸ | BCR | P11274 | 3/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717881 | 0.84 | MAPT (0.53) | TRPV1MAPTTHRBMAPK10KDM4E | |
| SCHEMBL4715969 | 0.83 | TRPV1 (0.69) | TRPV1ABL1BCRFAAHTHRB | |
| SCHEMBL1011763 | 0.81 | TRPV1 (0.64) | TRPV1ABL1BCRFAAH | |
| SCHEMBL1013757 | 0.80 | TRPV1 (0.78) | TRPV1ABL1BCRFAAH | |
| SCHEMBL4717536 | 0.80 | TRPV1 (0.61) | TRPV1ABL1BCRFAAHTHRB | |
| SCHEMBL4718506 | 0.80 | MAPT (0.53) | TRPV1MAPTTHRBMAPK10KDM4E | |
| SCHEMBL1013451 | 0.79 | TRPV1 (0.60) | TRPV1ABL1BCRFAAHMAPK10 | |
| SCHEMBL1013070 | 0.78 | TRPV1 (0.59) | TRPV1ABL1BCRFAAHTHRB | |
| SCHEMBL4715948 | 0.77 | TRPV1 (0.53) | TRPV1ABL1BCRFAAHTHRB | |
| SCHEMBL1013741 | 0.76 | TRPV1 (0.62) | TRPV1ABL1BCRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442701-B2 | Amino-heterocycles as VR-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2008-10-28 | — | — | US | disclosed |
| EP-1562934-B1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1562934-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046133-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | OPRL1, CNR1, GPR6 | TRPV1 40/4885MAPT 4864/4885ABL1 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.